Kiniksa Pharmaceuticals reported total product revenue of $285.97 million for the third quarter of 2026, a significant increase from $180.86 million in the prior year. Net income for the quarter rose to $47.35 million, while the company maintained a strong liquidity position with $568.76 million in cash, cash equivalents, and short-term investments.
Kiniksa Pharmaceuticals International Financial Results
Kiniksa Pharmaceuticals reported Q3 2026 financial results, highlighted by ARCALYST net product revenue of $286.0 million, a 58% year-over-year increase. The company raised its full-year 2026 ARCALYST net product revenue guidance to a range of $1.045 billion to $1.050 billion.
“Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis. In the third quarter, strong commercial execution led to gains in patient and physician adoption, resulting in revenue of $286.0 million and positioning ARCALYST to achieve blockbuster status this year”
Sanj K. Patel, Chairman & Chief Executive Officer of Kiniksa